NCT03620136

Brief Summary

The post-operative pain generated by prosthetic knee replacement surgery is known to be moderate to severe during two or three days following surgery. The most popular analgesic technique after prosthetic knee replacement surgery remains the femoral block (FB), whether in single injection or continuous infusion. In major knee surgery, FBs provide better analgesia compared to systemic morphine and FBs provide the same analgesia that obtained with epidural analgesia but with fewer associated adverse effects. Although FBs provide excellent post-operative analgesia after total knee prosthesis, they also provide a significant quadricepsia weakness that increases the risk of severe falls and complications, and hinders the rapid rehabilitation process. For these reasons, alternative analgesic techniques have emerged in recent years. To avoid the quadricipital motor block generated by FBs, some authors proposed the administration of local anesthetics in the adductor channel, also known as the Hunter channel, in order to produce a pure sensory block. With the development of ultrasound, the adductor channel is easily visualized in the middle of the thigh. This allows the adductor channel block (ACB) to be realized with a high success rate. ACB appears to decrease postoperative pain and morphine consumption. It also significantly improves the ability of patients to walk around after Total Knee Arthroplasty (TKA) surgery. With the same goal of quadricipital savings, the use of the analgesic technique by periarticular infiltration of local anesthetics (ILA) has spread in recent years, due to the fact that an analgesic technique of simple realization and without apparent danger, and this despite limited evidence of its effectiveness. The Croix-Rousse Hospital is a university hospital in Lyon with a highly developed orthopedic surgery center, producing approximately 550 TKA per year. During the year 2016, approximately half were benefited from post-operative analgesia management by ACB, and the other half by the implementation of the ILA. To date few studies have been interested in comparing these two analgesic techniques in knee prosthesis surgery.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
98

participants targeted

Target at P25-P50 for phase_3

Timeline
Completed

Started Feb 2018

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

November 14, 2017

Completed
3 months until next milestone

Study Start

First participant enrolled

February 7, 2018

Completed
6 months until next milestone

First Posted

Study publicly available on registry

August 8, 2018

Completed
1.3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 27, 2019

Completed
1 day until next milestone

Study Completion

Last participant's last visit for all outcomes

November 28, 2019

Completed
Last Updated

October 3, 2025

Status Verified

September 1, 2025

Enrollment Period

1.8 years

First QC Date

November 14, 2017

Last Update Submit

September 30, 2025

Conditions

Keywords

Total knee prosthesisAdductor canal blockLocal peri-articular infiltrationsPostoperative analgesiaEarly rehabilitationPatient Controlled Analgesia

Outcome Measures

Primary Outcomes (1)

  • the cumulative consumption of MORPHINE

    cumulative dose of morphine (miligrams). The administration of morphine will be done using a self-controlled analgesic pump (PCA). It will be made available to the patient when he leaves the block. The PCA allows the patient to adapt his consumption of morphine to his needs in analgesics. A nurse regularly reports the amount of morphine that the patient has administered.

    during the first 48 hours following the surgical incision

Secondary Outcomes (10)

  • Pain at rest

    Resting pain will be measured every 4 hours in the first 24 hours, then every 8 hours between 24 and 72 hours

  • pain in movement

    at day 3

  • quality of the analgesia offered by the ACB

    within 48 hours after the injection to the adductor channel

  • quality of the analgesia offered by the ILA

    within 48 hours after the end of surgery

  • quality of the analgesia

    within 48 hours after the surgical incision time

  • +5 more secondary outcomes

Study Arms (2)

locoregional analgesia by a block on the adductor channel

EXPERIMENTAL
Drug: locoregional analgesia by a block on the adductor channel

locoregional analgesia by periarticular local infiltrations

EXPERIMENTAL
Drug: locoregional analgesia by periarticular local infiltrations

Interventions

The block at the adductor channel will be realized under echo guidance, before the spinal anesthesia, by puncture at the upper 1/3 of the thigh. It will be used echogenic needle adapted to the morphotype of each patient, of varying length from 50mm to 100mm. A single injection of 20mL of ROPIVACAINE 2mg / ml, the efficacy of which should be checked before spinal anesthesia is performed by a cold test. Knee analgesia will be supplemented by per-operative infiltration of 50mL of ROPIVACAINE 2mg / ml at the posterior capsule, once the surfaces joints prepared to accommodate the prosthesis and by two placebo infiltrations of 50mL each of physiological saline in the medial and lateral ligaments and in the edges of the incision.

locoregional analgesia by a block on the adductor channel

A placebo injection to the adductor channel of 20 mL of physiological serum will be performed in the pre-induction room before surgery, according to the same procedures as the patients of the ACB group. During the surgical procedure, patients in the ILA group will receive a total dose of 300mg of ROPIVACAINE 2mg / ml in the form of 3 periarticular injections. The first injection of 50mL of ROPIVACAINE 2mg / ml will be made once the articular surfaces are prepared to receive the prosthesis, at the level of the posterior capsule. The second injection of 50mL of ROPIVACAINE 2mg / ml will be performed once the total knee prosthesis is installed, in the medial and lateral ligaments. Finally, the last injection will also include 50mL of ROPIVACAINE 2mg / ml and will be made in the edges of the incision at the time of closure.

locoregional analgesia by periarticular local infiltrations

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Major patients (≥18 years),
  • Having an American Society of Anesthesiology score (ASA) I to III
  • To benefit from first and unilateral prosthetic replacement surgery of knee under spinal anesthesia,
  • Having social security scheme,
  • Having received informed information and having signed informed consent

You may not qualify if:

  • Pregnant women (diagnosis of interrogation),
  • Breastfeeding women
  • Patients under tutorship or curatorship,
  • Persons who can not receive sufficient information because of disturbances of superior functions or because of insufficient command of the French language according to the judgment of the investigator,
  • A history of chronic neuropathic pain in the leg to be operated on,
  • Patients who have undergone prior surgery on the knee to perform surgery,
  • Contra-indication to loco-regional anesthesia: known allergy to local anesthetics,
  • Contra-indication to the use of ROPIVACAINE: known hypersensitivity to the active substance or other amide-linked local anesthetics, hypovolemia
  • A morbid obesity (Body Mass Index (BMI)\> 40),
  • Severe renal insufficiency (Glomerular Filtration Rate (GFR) \<30mL / min),
  • Severe hepatic impairment (prothrombin rate PR \<50%),
  • Heart failure (left ventricular ejection fraction (LVEF)\<40%),
  • Transplanted patients,
  • A history of drug abuse,
  • The taking of chronic morphine for 6 months in systematic,
  • +3 more criteria

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Croix Rousse Hospital

Lyon, 69004, France

Location

Related Publications (1)

  • Pic C, Macabeo C, Waissi E, Lasselin P, Raffin M, Pradat P, Lalande L, Lustig S, Aubrun F, Dziadzko M. No Benefit of Adductor Canal Block Compared with Anterior Local Infiltration Analgesia in Primary Total Knee Arthroplasty: A Single-Blinded Randomized Controlled Clinical Trial. J Bone Joint Surg Am. 2023 Feb 1;105(3):231-238. doi: 10.2106/JBJS.22.00745. Epub 2022 Nov 18.

Study Officials

  • Caroline Macabeo

    Hospices Civils de Lyon

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
phase 3
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
PARTICIPANT
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

November 14, 2017

First Posted

August 8, 2018

Study Start

February 7, 2018

Primary Completion

November 27, 2019

Study Completion

November 28, 2019

Last Updated

October 3, 2025

Record last verified: 2025-09

Locations